Advocacy intelligence hub — real-time data for patient organizations
Blueprint Medicines Corporation
Blueprint Medicines Corporation
Cogent Biosciences, Inc. — PHASE2
Blueprint Medicines Corporation — PHASE2, PHASE3
Telios Pharma, Inc. — PHASE2
Blueprint Medicines Corporation — PHASE2
Data from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.
FINANCIAL LANDSCAPE SUMMARY
Total programs
Ayvakit
(avapritinib)Orphan drugstandardBlueprint Medicines Corporation
Kinase Inhibitor [EPC]
12.1 Mechanism of Action Avapritinib is a tyrosine kinase inhibitor that targets KIT D816V, PDGFRA and PDGFRA D842 mutants as well as multiple KIT exo...
Marcus Maurer, MD
Charite University, Berlin, Germany
📍 PUEBLO, CO
Frank Siebenhaar, MD
Charite University, Berlin, Germany
Olivier Lortholary, MD, PhD
Hôpital Necker, Paris, France
Rachael Easton, MD, PhD, FNP-BC
Cogent Biosciences
📍 TROY, MI
Hirsh D Komarow, M.D., M.D
National Institute of Allergy and Infectious Diseases (NIAID)
📍 BETHESDA, MD
Anthony L Boral, MD, PhD, M.D
Blueprint Medicines Corporation
📍 CAMBRIDGE, MA